PROV-MESH: Prophylactic Ovarian Cancer MESH

Recruiting N/A Interventional Study
Ovarian Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Study type
Interventional
Purpose
Prevention
Participants needed
152 (estimated)
Sponsor
Hospital Vall d'Hebron · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Incisional hernia is a common complication after midline laparotomy and may significantly impact quality of life, morbidity, and healthcare costs. Patients undergoing cytoreductive surgery for ovarian cancer are considered at increased risk due to extensive surgical procedures, nutritional status, and exposure to systemic treatments. This prospective randomized clinical trial aims to evaluate whe…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Female patients diagnosed with ovarian carcinoma. * Undergoing primary cytoreductive surgery, interval cytoreductive surgery, or delayed cytoreductive surgery after six cycles of chemotherapy. * Surgical procedure performed through a midline laparotomy. * Ability and willingne…
Contacts

Jose Luis Sánchez Iglesias, MD PhD

+34 932746000

jlsanig@yahoo.es

CONTACT